2.54 USD
↗ 0.02 (0.79%)AT CLOSE (11:59 AM EDT)
Cellectar Biosciences INC NEW
CLRBNASDAQ • USD
2.59
↗ 0.05 (1.97%)
POST MARKET (AS OF 07:39 PM EDT)
Post Market
AS OF 07:39 PM EDT
2.59
↗ 0.05 (1.97%)
Market: OPEN
Shares of Cellectar Biosciences INC NEW (CLRB) are trading at $2.59. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation side, CLRB appears attractively valued relative to sector peers across key multiples.
Technical & fundamental data as of Aug 25, 2026.
Open?$2.59
High?$2.60
Low?$2.50
Prev. Close?$2.52
Volume?16.7K
Avg. Volume?63.9K
VWAP?$2.54
Rel. Volume?0.26x
Bid / Ask
Bid?$2.10 × 100
Ask?$2.91 × 100
Spread?$0.81
Midpoint?$2.51
Valuation & Ratios
Market Cap?23.8M
Shares Out?9.5M
Float?7.6M
Float %?94.7%
P/E Ratio?N/A
P/B Ratio?0.80
EPS?-$2.36
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Themes
Employees
11
Market Cap
23.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2005-04-19
Address
100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
Phone: (608) 441-8120
FLORHAM PARK, NJ 07932
Phone: (608) 441-8120
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?65
Short Sent.?63
Piotroski F-Score?0/9Weak
Altman Z-Score?-9.80Distress
Confidence?49%Low
Short InterestHigh
Short % of Float?2.13%Low
Short Interest?161.2K
Days to Cover?5.4
Free Float7.6M
Avg Daily Volume29.9K
Settlement Date2026-08-14
Financial Health
Current Ratio?6.66Strong
Quick Ratio?6.66Strong
Cash Ratio?6.49Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.80CHEAP▾
Peers100
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?0.4CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-74.7%WEAK▾
S&P3
ROA?-60.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-19484257
Enterprise Value?$-10174670
Fundamentals ratios updated end of day